Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$966.65

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $936.36 20
Education $30.29 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1699985002?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $966.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myriad Genetic Laboratories, Inc. $181.6512/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059761765 CMS
Myriad Genetic Laboratories, Inc. $233.5512/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059761767 CMS
Gilead Sciences, Inc. $4.1411/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026140799 CMS
E.R. Squibb & Sons, L.L.C. $12.3510/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077631 CMS
E.R. Squibb & Sons, L.L.C. $6.4510/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077641 CMS
Gilead Sciences, Inc. $3.5510/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026146747 CMS
Merck Sharp & Dohme LLC $101.2510/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048266767 CMS
E.R. Squibb & Sons, L.L.C. $16.9210/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077549 CMS
Gilead Sciences, Inc. $4.8010/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026133625 CMS
E.R. Squibb & Sons, L.L.C. $14.2409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077481 CMS
E.R. Squibb & Sons, L.L.C. $6.4409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077491 CMS
E.R. Squibb & Sons, L.L.C. $7.0808/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077419 CMS
E.R. Squibb & Sons, L.L.C. $2.7808/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077439 CMS
E.R. Squibb & Sons, L.L.C. $4.0108/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077449 CMS
AstraZeneca Pharmaceuticals LP $40.2707/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011829985 CMS
E.R. Squibb & Sons, L.L.C. $17.5206/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077265 CMS
E.R. Squibb & Sons, L.L.C. $6.8506/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077275 CMS
SANOFI PASTEUR INC. $24.2904/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044012631 CMS
Gilead Sciences, Inc. $124.9904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025507695 CMS
Apellis Pharmaceuticals, Inc. $30.2903/24/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056371113 CMS
E.R. Squibb & Sons, L.L.C. $123.2301/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015077379 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

318 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,786.78 12/31/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1155802756
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,784.00 12/31/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1155803536
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41.34 12/31/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1155803994
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,914.19 12/31/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1155804408
Principal investigator 1 AstraZeneca Pharmaceuticals LP $208.38 12/31/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1155804572
Principal investigator 1 Genentech, Inc. $145.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451062
Principal investigator 1 Genentech, Inc. $40.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451070
Principal investigator 1 Genentech, Inc. $100.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451122
Principal investigator 1 Genentech, Inc. $997.25 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451126
Principal investigator 1 Genentech, Inc. $198.75 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451224
Principal investigator 1 Genentech, Inc. $93.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451283
Principal investigator 1 Genentech, Inc. $125.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451302
Principal investigator 1 Genentech, Inc. $25.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451346
Principal investigator 1 Genentech, Inc. $1,104.25 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451381
Principal investigator 1 Genentech, Inc. $93.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451449
Principal investigator 1 Genentech, Inc. $1,200.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451516
Principal investigator 1 Genentech, Inc. $1,200.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451520
Principal investigator 1 Genentech, Inc. $100.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451672
Principal investigator 1 Genentech, Inc. $93.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451708
Principal investigator 1 Genentech, Inc. $220.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451712
Principal investigator 1 Genentech, Inc. $93.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451826
Principal investigator 1 Genentech, Inc. $198.75 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451886
Principal investigator 1 Genentech, Inc. $1,200.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451965
Principal investigator 1 Genentech, Inc. $93.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133452085
Principal investigator 1 Genentech, Inc. $658.00 12/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133452088
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,250.00 12/04/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1110836051
Principal investigator 1 Genentech, Inc. $293.00 11/19/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472601
Principal investigator 1 Genentech, Inc. $114.00 11/19/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472608
Principal investigator 1 Genentech, Inc. $142.00 11/19/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472616
Principal investigator 1 Genentech, Inc. $64.00 11/19/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472624
Principal investigator 1 Genentech, Inc. $454.00 11/19/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472640
Principal investigator 1 Genentech, Inc. $45.00 11/19/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472660
Principal investigator 1 PFIZER INC. $1,125.00 11/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1130933045
Principal investigator 1 Genentech, Inc. $866.25 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451054
Principal investigator 1 Genentech, Inc. $25.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451058
Principal investigator 1 Genentech, Inc. $1,068.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451086
Principal investigator 1 Genentech, Inc. $1,104.25 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451205
Principal investigator 1 Genentech, Inc. $220.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451338
Principal investigator 1 Genentech, Inc. $220.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451465
Principal investigator 1 Genentech, Inc. $1,037.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451508
Principal investigator 1 Genentech, Inc. $198.75 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451552
Principal investigator 1 Genentech, Inc. $1,208.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451556
Principal investigator 1 Genentech, Inc. $866.25 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451584
Principal investigator 1 Genentech, Inc. $507.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451592
Principal investigator 1 Genentech, Inc. $220.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451604
Principal investigator 1 Genentech, Inc. $198.75 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451648
Principal investigator 1 Genentech, Inc. $125.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451704
Principal investigator 1 Genentech, Inc. $940.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451744
Principal investigator 1 Genentech, Inc. $198.75 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133452076
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 11/15/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1127519483
Principal investigator 1 PFIZER INC. $295.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130927316
Principal investigator 1 PFIZER INC. $295.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130927320
Principal investigator 1 PFIZER INC. $295.00 11/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130927324
Principal investigator 1 Genentech, Inc. $1,500.00 11/13/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470916
Principal investigator 1 Genentech, Inc. $1,350.00 11/05/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472668
Principal investigator 1 Genentech, Inc. $22,680.00 10/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470276
Principal investigator 1 Genentech, Inc. $866.25 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451137
Principal investigator 1 Genentech, Inc. $1,148.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451141
Principal investigator 1 Genentech, Inc. $198.75 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451149
Principal investigator 1 Genentech, Inc. $1,016.25 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451165
Principal investigator 1 Genentech, Inc. $220.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451193
Principal investigator 1 Genentech, Inc. $506.62 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451236
Principal investigator 1 Genentech, Inc. $1,447.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451385
Principal investigator 1 Genentech, Inc. $198.75 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451405
Principal investigator 1 Genentech, Inc. $220.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451409
Principal investigator 1 Genentech, Inc. $100.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451493
Principal investigator 1 Genentech, Inc. $198.75 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451524
Principal investigator 1 Genentech, Inc. $866.25 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451612
Principal investigator 1 Genentech, Inc. $198.75 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451664
Principal investigator 1 Genentech, Inc. $866.25 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451763
Principal investigator 1 Genentech, Inc. $997.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451787
Principal investigator 1 Genentech, Inc. $956.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451803
Principal investigator 1 Genentech, Inc. $99.38 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451929
Principal investigator 1 Genentech, Inc. $36.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133451977
Principal investigator 1 PFIZER INC. $956.00 10/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130927164
Principal investigator 1 Genentech, Inc. $170.00 10/11/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470272
Principal investigator 1 Genentech, Inc. $114.00 10/11/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470329
Principal investigator 1 Genentech, Inc. $536.00 10/11/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470511
Principal investigator 1 Genentech, Inc. $170.00 10/09/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470620
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470009
Principal investigator 1 Genentech, Inc. $536.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470012
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470063
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470102
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470127
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470131
Principal investigator 1 Genentech, Inc. $536.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470195
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470228
Principal investigator 1 Genentech, Inc. $170.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470285
Principal investigator 1 Genentech, Inc. $28.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470333
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470337
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470365
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470459
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470463
Principal investigator 1 Genentech, Inc. $170.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470475
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470491
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470535
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470560
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470564
Principal investigator 1 Genentech, Inc. $28.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470568
Principal investigator 1 Genentech, Inc. $536.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470572
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470612
Principal investigator 1 Genentech, Inc. $45.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470639
Principal investigator 1 Genentech, Inc. $536.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470679
Principal investigator 1 Genentech, Inc. $536.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470687
Principal investigator 1 Genentech, Inc. $536.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470691
Principal investigator 1 Genentech, Inc. $114.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470695
Principal investigator 1 Genentech, Inc. $170.00 10/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133470758
Principal investigator 1 Genentech, Inc. $536.00 09/25/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133469708
Principal investigator 1 Genentech, Inc. $5,111.00 09/24/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472553
Principal investigator 1 Genentech, Inc. $198.75 09/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447960
Principal investigator 1 Genentech, Inc. $866.25 09/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448540
Principal investigator 1 Genentech, Inc. $866.25 09/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448671
Principal investigator 1 Genentech, Inc. $866.25 09/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448844
Principal investigator 1 Genentech, Inc. $198.75 09/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449720
Principal investigator 1 Genentech, Inc. $198.75 09/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450768
Principal investigator 1 Genentech, Inc. $1,500.00 08/21/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133469783
Principal investigator 1 Genentech, Inc. $1,104.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447908
Principal investigator 1 Genentech, Inc. $198.75 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447984
Principal investigator 1 Genentech, Inc. $198.75 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448040
Principal investigator 1 Genentech, Inc. $176.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448152
Principal investigator 1 Genentech, Inc. $997.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448206
Principal investigator 1 Genentech, Inc. $40.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448404
Principal investigator 1 Genentech, Inc. $472.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448448
Principal investigator 1 Genentech, Inc. $36.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448612
Principal investigator 1 Genentech, Inc. $75.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448730
Principal investigator 1 Genentech, Inc. $25.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448816
Principal investigator 1 Genentech, Inc. $506.62 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448840
Principal investigator 1 Genentech, Inc. $127.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449029
Principal investigator 1 Genentech, Inc. $100.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449049
Principal investigator 1 Genentech, Inc. $40.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449057
Principal investigator 1 Genentech, Inc. $99.38 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449252
Principal investigator 1 Genentech, Inc. $75.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449435
Principal investigator 1 Genentech, Inc. $997.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449474
Principal investigator 1 Genentech, Inc. $42.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449653
Principal investigator 1 Genentech, Inc. $40.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449673
Principal investigator 1 Genentech, Inc. $75.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449797
Principal investigator 1 Genentech, Inc. $100.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449921
Principal investigator 1 Genentech, Inc. $198.75 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449965
Principal investigator 1 Genentech, Inc. $100.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449969
Principal investigator 1 Genentech, Inc. $40.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450048
Principal investigator 1 Genentech, Inc. $1,032.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450057
Principal investigator 1 Genentech, Inc. $101.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450098
Principal investigator 1 Genentech, Inc. $36.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450126
Principal investigator 1 Genentech, Inc. $176.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450154
Principal investigator 1 Genentech, Inc. $198.75 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450162
Principal investigator 1 Genentech, Inc. $198.75 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450331
Principal investigator 1 Genentech, Inc. $100.00 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450955
Principal investigator 1 Genentech, Inc. $997.25 08/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451014
Principal investigator 1 Genentech, Inc. $19,842.00 08/14/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133469584
Principal investigator 1 Genentech, Inc. $1,148.00 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133448121
Principal investigator 1 Genentech, Inc. $40.00 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449090
Principal investigator 1 Genentech, Inc. $198.75 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449347
Principal investigator 1 Genentech, Inc. $956.00 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449482
Principal investigator 1 Genentech, Inc. $997.25 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449937
Principal investigator 1 Genentech, Inc. $1,016.25 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450471
Principal investigator 1 Genentech, Inc. $198.75 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450502
Principal investigator 1 Genentech, Inc. $100.00 07/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450919
Principal investigator 1 Genentech, Inc. $570.00 07/05/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133469940
Principal investigator 1 Veru Inc. $97.50 06/17/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
VERU001_V2000701_80052317 No dispute reported 06/30/2026 1147595716
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448057
Principal investigator 1 Genentech, Inc. $198.75 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448172
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448292
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448368
Principal investigator 1 Genentech, Inc. $198.75 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448416
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448856
Principal investigator 1 Genentech, Inc. $198.75 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448859
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448890
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448933
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449153
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449343
Principal investigator 1 Genentech, Inc. $40.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449379
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449419
Principal investigator 1 Genentech, Inc. $23.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449522
Principal investigator 1 Genentech, Inc. $997.25 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449601
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449641
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449685
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449725
Principal investigator 1 Genentech, Inc. $25.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449799
Principal investigator 1 Genentech, Inc. $40.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449893
Principal investigator 1 Genentech, Inc. $40.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450012
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450260
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450268
Principal investigator 1 Genentech, Inc. $997.25 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450288
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450665
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450760
Principal investigator 1 Genentech, Inc. $100.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450800
Principal investigator 1 Genentech, Inc. $1,104.25 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450812
Principal investigator 1 PFIZER INC. $295.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130943219
Principal investigator 1 PFIZER INC. $295.00 06/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130943370
Principal investigator 1 Genentech, Inc. $19,815.00 06/07/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133468857
Principal investigator 1 Genentech, Inc. $1,500.00 06/07/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133469061
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 05/23/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1127519485
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 05/23/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1127519487
Principal investigator 1 Genentech, Inc. $1,350.00 05/21/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133472222
Principal investigator 1 Genentech, Inc. $100.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447924
Principal investigator 1 Genentech, Inc. $1,016.25 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447936
Principal investigator 1 Genentech, Inc. $198.75 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448036
Principal investigator 1 Genentech, Inc. $198.75 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448288
Principal investigator 1 Genentech, Inc. $198.75 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448328
Principal investigator 1 Genentech, Inc. $100.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448396
Principal investigator 1 Genentech, Inc. $100.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448945
Principal investigator 1 Genentech, Inc. $866.25 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449037
Principal investigator 1 Genentech, Inc. $1,016.25 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449815
Principal investigator 1 Genentech, Inc. $198.75 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449868
Principal investigator 1 Genentech, Inc. $830.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450103
Principal investigator 1 Genentech, Inc. $100.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450107
Principal investigator 1 Genentech, Inc. $198.75 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450138
Principal investigator 1 Genentech, Inc. $866.25 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450181
Principal investigator 1 Genentech, Inc. $198.75 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450300
Principal investigator 1 Genentech, Inc. $830.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450403
Principal investigator 1 Genentech, Inc. $100.00 05/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450490
Principal investigator 1 Genentech, Inc. $28.00 05/10/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133468949
Principal investigator 1 Genentech, Inc. $40.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447880
Principal investigator 1 Genentech, Inc. $472.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447928
Principal investigator 1 Genentech, Inc. $956.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448005
Principal investigator 1 Genentech, Inc. $198.75 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448061
Principal investigator 1 Genentech, Inc. $265.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448218
Principal investigator 1 Genentech, Inc. $100.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448568
Principal investigator 1 Genentech, Inc. $1,148.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133448985
Principal investigator 1 Genentech, Inc. $40.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449093
Principal investigator 1 Genentech, Inc. $1,080.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449205
Principal investigator 1 Genentech, Inc. $198.75 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449897
Principal investigator 1 Genentech, Inc. $1,013.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450170
Principal investigator 1 Genentech, Inc. $1,250.25 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450836
Principal investigator 1 Genentech, Inc. $150.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450867
Principal investigator 1 Genentech, Inc. $61.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450938
Principal investigator 1 PFIZER INC. $956.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130943214
Principal investigator 1 PFIZER INC. $765.00 04/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1130961042
Principal investigator 1 Veru Inc. $216.67 04/15/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
VERU001_V2000701_80052317 No dispute reported 06/30/2026 1147595658
Principal investigator 1 Genentech, Inc. $507.00 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447944
Principal investigator 1 Genentech, Inc. $198.75 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448241
Principal investigator 1 Genentech, Inc. $1,100.25 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448461
Principal investigator 1 Genentech, Inc. $198.75 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448950
Principal investigator 1 Genentech, Inc. $25.00 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449133
Principal investigator 1 Genentech, Inc. $198.75 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449562
Principal investigator 1 Genentech, Inc. $1,250.25 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449763
Principal investigator 1 Genentech, Inc. $99.38 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449856
Principal investigator 1 Genentech, Inc. $1,100.25 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450024
Principal investigator 1 PFIZER INC. $295.00 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130942940
Principal investigator 1 PFIZER INC. $295.00 03/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130943365
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,900.00 03/13/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 1110837624
Principal investigator 1 Genentech, Inc. $1,500.00 03/13/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133468363
Principal investigator 1 Genentech, Inc. $6,802.00 03/13/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133468668
Principal investigator 1 Eli Lilly and Company $0.01 03/04/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1137367925
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,214.26 02/23/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1110838040
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133447992
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448140
Principal investigator 1 Genentech, Inc. $150.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448269
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448344
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448388
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448408
Principal investigator 1 Genentech, Inc. $472.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448445
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448476
Principal investigator 1 Genentech, Inc. $1,338.25 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448480
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448512
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448552
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448560
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448639
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448702
Principal investigator 1 Genentech, Inc. $472.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448722
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448773
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448824
Principal investigator 1 Genentech, Inc. $472.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449026
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449033
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449085
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449295
Principal investigator 1 Genentech, Inc. $61.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449359
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449368
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449458
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449665
Principal investigator 1 Genentech, Inc. $1,338.25 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449865
Principal investigator 1 Genentech, Inc. $61.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449885
Principal investigator 1 Genentech, Inc. $534.12 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449946
Principal investigator 1 Genentech, Inc. $1,289.25 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449949
Principal investigator 1 Genentech, Inc. $150.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450028
Principal investigator 1 Genentech, Inc. $150.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450040
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450134
Principal investigator 1 Genentech, Inc. $61.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450178
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450292
Principal investigator 1 Genentech, Inc. $61.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450296
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450392
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450423
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450482
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450561
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450621
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450633
Principal investigator 1 Genentech, Inc. $40.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450764
Principal investigator 1 Genentech, Inc. $472.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450828
Principal investigator 1 Genentech, Inc. $100.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450927
Principal investigator 1 Genentech, Inc. $198.75 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450978
Principal investigator 1 Genentech, Inc. $1,266.25 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133451026
Principal investigator 1 PFIZER INC. $988.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1130960907
Principal investigator 1 PFIZER INC. $1,389.00 02/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1130960972
Principal investigator 1 Genentech, Inc. $1,350.00 02/13/2024 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133471998
Principal investigator 1 GlaxoSmithKline, LLC. $4,911.56 02/05/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S No dispute reported 06/30/2026 1127519481
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,208.10 01/31/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1110842616
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,972.01 01/24/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1110835671
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,042.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1110837860
Principal investigator 1 AstraZeneca Pharmaceuticals LP $850.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 1110840886
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,881.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1110841180
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,216.80 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1110844312
Principal investigator 1 Eli Lilly and Company $9,169.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1137368074
Principal investigator 1 Eli Lilly and Company $3,824.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1137369102
Principal investigator 1 Genentech, Inc. $956.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448168
Principal investigator 1 Genentech, Inc. $472.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448420
Principal investigator 1 Genentech, Inc. $100.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448472
Principal investigator 1 Genentech, Inc. $40.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448500
Principal investigator 1 Genentech, Inc. $40.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133448572
Principal investigator 1 Genentech, Inc. $472.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449299
Principal investigator 1 Genentech, Inc. $100.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449713
Principal investigator 1 Genentech, Inc. $198.75 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133449811
Principal investigator 1 Genentech, Inc. $1,266.25 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1133450020
Principal investigator 1 Genentech, Inc. $1,148.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1133450541
Principal investigator 1 PFIZER INC. $956.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130942946
Principal investigator 1 PFIZER INC. $765.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1130960977
Principal investigator 1 PFIZER INC. $164.50 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1130961036
Principal investigator 1 PFIZER INC. $460.00 01/15/2024 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 1130961077
Principal investigator 1 Eli Lilly and Company $7,416.00 01/02/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1137369186